You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

PECULIARITIES OF TREATMENT OF IRRITABLE BOWEL SYNDROME IN PERSONS OF ORGANIZED STUDENT POPULATION

PECULIARITIES OF TREATMENT OF IRRITABLE BOWEL SYNDROME IN PERSONS OF ORGANIZED STUDENT POPULATION

https://doi.org/10.33573/ujoh2015.02.053

Nesen A. O., Chyrva O. V.

PECULIARITIES OF TREATMENT OF IRRITABLE BOWEL SYNDROME IN PERSONS OF ORGANIZED STUDENT POPULATION

SI "National institute of therapy named after L. T. Malaya of NAMS of Ukraine", Kharkiv

Full article (PDF), UKR

Introduction. Students are at increased risk of the combined functional pathology, caused by a combination of unfavorable factors, such as constant mental and emotional stress, informational stress, insufficient material provision, need to combine study with work, frequent violations disturbances in work, rest and nutrition, smoking, alcohol consumption.

Purpose. To increase the effectiveness of treatment of irritable bowel syndrome (IBS) in persons of organized student population by additional prescription of herbal preparation – Iberogast.

Materials and methods. The study was performed on 305 persons (181 (59,3 %) females and 124 (40,7%) males) of mean age (20,8 ± 0,1). All patients were divided into two groups: I – IBS patients, 6,6 % (20 individuals), II – patients with "overlap syndrome" of functional diseases of the digestive system (FDDS) – 5,2 % (16 individuals). Non-pharmacological treatment, including modification of trigger factors of lifestyle and nutrition, was conducted in patients with IBS. Depending on the designated medical treatment, patients were divided into two groups: treatment "A" (n = 18) – combined therapy with prescription of non-drug interventions, diet lowFODMAPs, phytopreparation "Iberogast" and, if necessary, from the 4th week – pantoprazole – 20 mg 2 per day and itopride hydrochloride – 50 mg 3 times a day. The treatment "B" (n = 18) – didn’t include herbal medicine. The treatment covered 8 weeks.

Results. IBS was diagnosed in 11,8 % of the examined persons, 44,4 % patients with IBS had an "overlap syndrome" of FDDS. On the 28th day of treatment, all persons noted improvement in health and reducing the intensity of complaints from

(210,1 ± 11,3) to (96,8 ± 7,2) points according to the IBS-SSS scale (r = 0,776, p < 0,001) and on the 56th day – up to (35,6 ± 4,2) points (r = 0,601, p < 0,001). When evaluating indices of the total IBS-SSS score in patients after 4 weeks of therapy the therapeutic response in group "A" was better (83.6±8.8) comparing with (110,0 ± 10,7) points in group "B" (p = 0,066). The total score IBS-SSS decreased by (64,9 ± 2,2) % (28th day) in patients receiving Iberogast, while in patients with "B" treatment this indicator was significantly lower – (43,3 ± 2,0) %, p < 0,001. A comparison of the total score IBS-SSS on the 56th day of treatment revealed no significant differences in the studied groups. However, the percentage of the total dynamics of IBS-SSS scores in the course of therapy was significantly different – -(88,7 ± 1,8) in group "A" and -(78,3 ± 2,3)% in group "B", p = 0,001.

Conclusions. The revealed peculiarities in the response to therapy in patients with IBS show pronounced efficiency of the combined treatment, including prescription of herbal medicine, changes in lifestyle and nutrition. Additional prescriptions of herbal medicines with a multifactorial effect on the digestive system – Iberogast, having shown its efficacy already in 4 weeks of therapy, promoted better leveling of clinical manifestations of IBS after the eight-week course of treatment.

Key words: irritable bowel syndrome, "overlap syndrome", clinical manifestations, herbal medicine, population of students

References

  1. Borovikov, V. 2003, Statistics. Skill of computer data analysis. SPb. : Piter, 688 p. (in Russian).
  2. Zosimov, A. N., Parhomenko, L. K. 2008, Evidence – based review of medical theses. Kh. : Fakt, 151 p. (in Russian).
  3. Osipenko, M. F., But-Gusaim, V. I., Voloshina, N. B. 2008, "An "overlap syndrome": irritable bowel syndrome and functional disorders of the biliary tract", Siberian Medical Journal, no. 5, pp. 21–26 (in Russian).
  4. Digesu, G. A., Panayi, D., Kundi, N. 2010, "Validity of the Rome III Criteria in assessing constipation in women", Int Urogynecol J., no. 21, pp. 1185–1193.https://doi.org/10.1007/s00192-010-1179-0
  5. Drossman, D. A., Chang, L., Bellamy, N. 2011, "Severity in Irritable Bowel Syndrome: A Rome Foundation Working Team Report", Am J. Gastroenterology, no. 106 (10), pp. 1749–1759.https://doi.org/10.1038/ajg.2011.201
  6. Ford, A. C., Marwaha, A., Lim A., Moayyedi P. 2010, "Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia", Clin Gastroenterol Hepatol, no. 8 (5), pp. 401–409. https://doi.org/10.1016/S0016-5085(09)60671-5
  7. Hunt, R., Quigley, E. 2013, WGO Global Guideline – Coping with common GI symptoms in the community’ World Gastroenterology Organization, pp. 1–37.
  8. Matsuzaki, J., Suzuki, H. 2012, "Classification of functional dyspepsia based on concomitant bowel symptoms Neurogastroenterol Motil", no. 24 (4), pp. 325-e164.https://doi.org/10.1111/j.1365-2982.2011.01859.x
  9. Noh, Y. W., Jung, H. K., Kim, S. E., Jung, S. A. 2010, "Overlap of erosive and non-erosive reflux diseases with functional gastrointestinal disorders according to Rome III Criteria", J. Neurogastroenterol Motil, no. 16 (2), pp. 148–156.https://doi.org/10.5056/jnm.2010.16.2.148
  10. Shadi, S. Y., Christie, J. 2013, "Functional Dyspepsia in Review: Pathophysiology and challenges in the diagnosis and management due to coexisting gastroesophageal reflux disease and irritable bowel syndrome", Gastroenterol Res Pract., ID351086, pp. 1–8. https://doi.org/10.1155/2013/351086
  11. Vakil, N., Halling, K., Ohlsson, L., Wernersson, B. 2013, "Symptom overlap between postprandial distress and epigastric pain syndromes of the Rome III dyspepsia classification", Am J. Gastroenterol, no. 108 (5), pp. 767–774. https://doi.org/10.1038/ajg.2013.89